203 related articles for article (PubMed ID: 19664754)
1. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
Sen HN; Levy-Clarke G; Faia LJ; Li Z; Yeh S; Barron KS; Ryan JG; Hammel K; Nussenblatt RB
Am J Ophthalmol; 2009 Nov; 148(5):696-703.e1. PubMed ID: 19664754
[TBL] [Abstract][Full Text] [Related]
2. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
Yeh S; Wroblewski K; Buggage R; Li Z; Kurup SK; Sen HN; Dahr S; Sran P; Reed GF; Robinson R; Ragheb JA; Waldmann TA; Nussenblatt RB
J Autoimmun; 2008 Sep; 31(2):91-7. PubMed ID: 18571896
[TBL] [Abstract][Full Text] [Related]
3. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
[TBL] [Abstract][Full Text] [Related]
4. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
5. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.
Kenawy N; Cleary G; Mewar D; Beare N; Chandna A; Pearce I
Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):297-300. PubMed ID: 20922440
[TBL] [Abstract][Full Text] [Related]
6. Intravenous daclizumab for recalcitrant ocular inflammatory disease.
Bhat P; Castañeda-Cervantes RA; Doctor PP; Foster CS
Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):687-92. PubMed ID: 19198869
[TBL] [Abstract][Full Text] [Related]
7. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.
Nussenblatt RB; Fortin E; Schiffman R; Rizzo L; Smith J; Van Veldhuisen P; Sran P; Yaffe A; Goldman CK; Waldmann TA; Whitcup SM
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7462-6. PubMed ID: 10377437
[TBL] [Abstract][Full Text] [Related]
8. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for juvenile idiopathic arthritis-associated uveitis.
Magli A; Forte R; Navarro P; Russo G; Orlando F; Latanza L; Alessio M
Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1601-6. PubMed ID: 23446556
[TBL] [Abstract][Full Text] [Related]
10. Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial.
Sen HN; Larson TA; Meleth AD; Smith WM; Nussenblatt RB
Am J Ophthalmol; 2012 Jun; 153(6):1038-42. PubMed ID: 22465364
[TBL] [Abstract][Full Text] [Related]
11. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
Quartier P; Baptiste A; Despert V; Allain-Launay E; Koné-Paut I; Belot A; Kodjikian L; Monnet D; Weber M; Elie C; Bodaghi B;
Ann Rheum Dis; 2018 Jul; 77(7):1003-1011. PubMed ID: 29275333
[TBL] [Abstract][Full Text] [Related]
12. Managing juvenile idiopathic arthritis-associated uveitis.
Hawkins MJ; Dick AD; Lee RJ; Ramanan AV; Carreño E; Guly CM; Ross AH
Surv Ophthalmol; 2016; 61(2):197-210. PubMed ID: 26599495
[TBL] [Abstract][Full Text] [Related]
13. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.
Wroblewski K; Sen HN; Yeh S; Faia L; Li Z; Sran P; Gangaputra S; Vitale S; Sherry P; Nussenblatt R
Can J Ophthalmol; 2011 Aug; 46(4):322-8. PubMed ID: 21816251
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.
Gregory AC; Kempen JH; Daniel E; Kaçmaz RO; Foster CS; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE;
Ophthalmology; 2013 Jan; 120(1):186-92. PubMed ID: 23062650
[TBL] [Abstract][Full Text] [Related]
16. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
Tynjälä P; Kotaniemi K; Lindahl P; Latva K; Aalto K; Honkanen V; Lahdenne P
Rheumatology (Oxford); 2008 Mar; 47(3):339-44. PubMed ID: 18238789
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
